SURE SWITZERLAND: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURE SWITZERLAND
- Sponsors Novo Nordisk
- 21 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2019 Status changed from active, no longer recruiting to recruiting.
- 14 May 2019 Status changed from recruiting to active, no longer recruiting.